Endothelial P-Selectin as a Target of Heparin Action in Experimental Melanoma Lung Metastasis

Ralf J. Ludwig(University of Lübeck), Jens Gille(Goethe University Frankfurt), Thomas M. Zollner(Bayer (Germany)), Beatrice Boehme(Goethe University Frankfurt), Reinhard Henschler(German Red Cross), Wolf‐Henning Boehncke(University Hospital of Geneva), Maurizio Podda(Goethe University Frankfurt), Christa Tandi(Goethe University Frankfurt), Elke Jäger(Krankenhaus Nordwest), Roland Kaufmann(Robert Koch Institute)

Cancer Research

April 15, 2004

10.1158/0008-5472.can-03-1054

Cited by 195

Related Papers

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

|Journal of Clinical Oncology|2008|784

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738

Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

|European Journal of Cancer|2019|589

Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition

|BMC Cancer|2012|561

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

|Journal of Clinical Oncology|2009|545